News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

35,144 signal articles · 107 in last 24h · 178,660 total before filter · latest 1h ago

107last 24h

3127last 7d

512● bullish (7d)

311● bearish (7d)

227publishers

All Macro103 Earnings1821 M&A172 Regulatory23 Product26 Analyst28

✕ clear all filtersticker: ABBVsentiment: neutralSentiment:bullish neutral bearish show all (incl. clickbait)

Trefis1d agoneutral

What Could Stall AbbVie Stock's Run?

ABBV BMY JNJ LLY MRK PFE SPGI ^GSPC

MarketBeat2d agoneutral

REGENXBIO Q3 Earnings Call Highlights

ABBV

MT Newswires2d agoneutral

Argus Adjusts Price Target on AbbVie to $320 From $270

ABBV

Barchart3d agoneutral

Are Wall Street Analysts Bullish on AbbVie Stock?

ABBV

24/7 Wall St.5d agoneutral

AbbVie Hit a New High After Earnings. There’s More Upside Left.

ABBV BMY JNJ

MT Newswires5d agoneutral

BNP Paribas Adjusts Price Target on AbbVie to $269 From $247

ABBV

MT Newswires6d agoneutral

Canaccord Genuity Adjusts Price Target on AbbVie to $338 From $290

ABBV

MT Newswires6d agoneutral

Leerink Partners Adjusts Price Target on AbbVie to $325 From $279

ABBV

Zacks6d agoneutral

ABBV Q3 Earnings Call Highlights Raised Outlook and Pipeline Progress

ABBV

MT Newswires6d agoneutral

Goldman Sachs Adjusts Price Target on AbbVie to $313 From $294

ABBV

MT Newswires6d agoneutral

Cantor Fitzgerald Adjusts Price Target on AbbVie to $325 From $290

ABBV

MT Newswires6d agoneutral

Guggenheim Adjusts Price Target on AbbVie to $322 From $288

ABBV

Motley Fool8d agoneutral

AbbVie: 3 Key Takeaways for Long-Term Investors

ABBV

GuruFocus.com8d agoneutral

AbbVie Inc (ABBV) Q3 2026 Earnings Call Highlights: Raised Guidance, Immunology Momentum, and a ...

ABBV

The Wall Street Journal9d agoneutral

Health Care Roundup: Market Talk

ABBV ABT

Motley Fool9d agoneutral

AbbVie (ABBV) Q3 2026 Earnings Call Transcript

ABBV

24/7 Wall St.39d agoneutral

BofA Boosts AbbVie and J&J Price Targets on Growth and Pipeline Strength

ABBV JNJ

Simply Wall St.40d agoneutral

Is AbbVie (ABBV) A Bargain After FDA Approval Of JUVMO For Parkinson's?

ABBV

Insider Monkey41d agoneutral

Can AbbVie’s Backing Help ADARx Win Over Biotech IPO Investors at a $1.74 Billion Valuation?

ABBV

TIKR41d agoneutral

AbbVie Won FDA Approval for Parkinson’s Pill Juvmo. Here’s Why Management Already Expects a Slow Start

ABBV

GuruFocus.com41d agoneutral

AbbVie Just Won an FDA First in Parkinson's Disease

ABBV

InvestorsHub41d agoneutral

AbbVie Receives FDA Approval for Parkinson’s Disease Drug Juvmo

ABBV

Quartz44d agoneutral

ADARx Pharmaceuticals raises $446 million in upsized IPO

ABBV

The Wall Street Journal44d agoneutral

The Peptide Boom That Isn’t About Your Muscles

ABBV AMGN JNJ

BioPharma Dive45d agoneutral

RNAi drug specialist ADARx raises $446M IPO

ABBV

Insider Monkey46d agoneutral

Nvidia Backed This AI Drug Startup. AbbVie Just Became a Partner Before Its IPO

ABBV MRK

Trefis46d agoneutral

What Is AbbVie No Longer Telling You?

ABBV BMY JNJ LLY MRK PFE

StockStory47d agoneutral

Reflecting On Therapeutics Stocks’ Q2 Earnings: AbbVie (NYSE:ABBV)

ABBV ABT

InvestorsHub47d agoneutral

AbbVie Secures EU Approval for Rinvoq in Juvenile Arthritis

ABBV

Trefis52d agoneutral

What Happens To AbbVie Stock If SKYRIZI Slows Down?

ABBV BMY JNJ LLY MRK PFE